EDP-1815 is a biologic commercialized by Evelo Biosciences, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 9 clinical trials, of which 6 were completed, 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of EDP-1815’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for EDP-1815 is expected to reach an annual total of $20 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EDP-1815 is under development for the treatment of rheumatoid arthritis, skin inflammation, psoriasis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The therapeutic candidate is administered through oral route as a capsule. It is non-live single strain bacterial-based therapeutics that acts by down-regulating the immune system.
It was under development for the treatment of influenza viral infection, atopic dermatitis and also for coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Evelo Biosciences Overview
Evelo Biosciences is a biotechnology company. It develops orally delivered product candidates for the treatment of inflammatory diseases and cancer. The company is investigating pipeline product EDP1815 and EDP1867, targeting SARS-CoV-2 virus, psoriasis, atopic dermatitis, and inflammatory diseases; and EDP1908, an anti-PD-1 therapy for multiple cancers. Its proprietary Sintax, an integrated platform develops oral biologics which harness the cells in the small intestine. Evelo Biosciences is also evaluating novel therapies to treat chronic diseases and cancer. The company’s Evelo is a trademark of Evelo Biosciences. It has its operations in the US, and the UK. Evelo Biosciences is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$109 million in FY2022, compared to an operating loss of US$118.6 million in FY2021. The net loss of the company was US$114.5 million in FY2022, compared to a net loss of US$122.2 million in FY2021.
For a complete picture of EDP-1815’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.